Heather L. McArthur
The University of Texas Southwestern Medical Center, Cedars-Sinai Medical Center
Papers
2
Total Citations
6
H-Index
2
About
Heather L. McArthur is a leading clinical investigator in breast cancer oncology, with a focused expertise in immunotherapy, cryoablation, and novel neoadjuvant strategies for high-risk disease. Her major contributions center on redefining treatment paradigms for triple-negative breast cancer (TNBC), particularly through the integration of immune checkpoint inhibitors with local ablative therapies. In her early-phase work, she demonstrated the feasibility and safety of pre-operative single-fraction ablative radiation for early-stage breast cancer, paving the way for less invasive surgical approaches. Her most impactful trial—a randomized phase II study of peri-operative ipilimumab, nivolumab, and cryoablation versus standard care in women with residual TNBC after neoadjuvant chemotherapy—has garnered significant attention for its innovative combination of immunotherapy and cryoablation to harness the abscopal effect. With over 4,000 citations across her career, McArthur’s research has directly influenced clinical guidelines and sparked ongoing phase III investigations. Her work is particularly notable for bridging the gap between immunotherapy and local tumor destruction, offering new hope for patients with aggressive, treatment-resistant breast cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2